CRRTF News and Press, Coronet Carpets Inc From 11/09/22

Crescita Therapeutics press release ( OTCPK:CRRTF ): Q3 GAAP EPS of C$0.01. Revenue of C$6.03M (+101.7% Y/Y). For further details see: Crescita Therapeutics GAAP EPS of C$0.01, revenue of C$6.03M

Sales Doubled with New Manufacturing Revenue Record of $4.3M Adjusted EBITDA 1 of $0.5M, up $1.0M Year-over-Year Cash Balance of $10.7M Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a gr...

Crescita Therapeutics press release ( OTCPK:CRRTF ): Q2 GAAP EPS of C$0.00. Revenue of C$6.51M (+121.4% Y/Y). For further details see: Crescita Therapeutics GAAP EPS of C$0.00, revenue of C$6.51M

Over 120% sales growth with Record Manufacturing Revenue of $3.9M Adjusted EBITDA 1 of $0.6M, up $0.9M Year-over-Year Repayment of $1.0 M of Convertible Debentures Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the &#...

Crescita Therapeutics press release (OTC:CRRTF): Q1 GAAP EPS of -C$0.02. Revenue of C$4.95M (+51.4% Y/Y). Adjusted EBITDA was C$66K compared to C$87K. Ending cash was C$11.74M compared to C$11.33M at the end of Q4-F2021, representing cash generation of $411K for the quarter. For further det...

Record Manufacturing Segment Revenue of $3.4M Positive Adjusted EBITDA 1 Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology compan...

Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”) today announced that its CEO, Serge Verreault, will be presenting at the 2022 Bloom Burton & Co. Healthcare Investor Conference, to be held on May 2 and 3, 2022, featuring...

Crescita Therapeutics press release (OTC:CRRTF): Q4 GAAP EPS of C$0.04. Revenue of C$7.56M (+171.0% Y/Y). For further details see: Crescita Therapeutics GAAP EPS of C$0.04, revenue of C$7.56M

– Record Q4, and F2021 Manufacturing Segment Revenue of $5.3M, a 3-fold Increase vs. F2020 – Expansion of Pliaglis ® Licenses to 32 New Countries – Strong Liquidity Position of $11.3M – Q4-F2021 Adjusted EBITDA 1 of $1.6M Crescita T...

Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“ Crescita ” or the “ Company ”) announced today that the Toronto Stock Exchange (the “ TSX ”) has approved the Company’s renewal of its existing normal course issuer bid ...